Overview

• US medical device maker's fiscal Q3 revenue rose 8.9%, beating analyst expectations

• Adjusted EPS loss for fiscal Q3 narrowed and beat analyst expectations

• Company raised full-year guidance for net sales and adjusted EBITDA

Outlook

• AngioDynamics raises FY 2026 net sales guidance to $313.5-$315.5 mln from $312-$314 mln

• Company lifts FY 2026 adjusted EBITDA forecast to $10-$12 mln from $8-$10 mln

• AngioDynamics expects FY 2026 cash flow may be slightly negative due to inventory build

Result Drivers

• MED TECH GROWTH - Double-digit growth in Med Tech segment, led by Auryon, mechanical thrombectomy (AlphaVac and AngioVac), and NanoKnife platforms

• TARIFFS AND COST INFLATION - Gross margin declined due to tariffs, inflation, and manufacturing transition costs, in line with expectations

• OPERATING DISCIPLINE - Profitability supported by disciplined execution of operating initiatives

Company press release: ID:nBwbjKjCGa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Sales	Beat	$78.4 mln	$76.77 mln (3 Analysts)
Q3 Adjusted EPS	Beat	-$0.07	-$0.11 (3 Analysts)
Q3 Adjusted Net Income	Beat	-$3 mln	-$4.45 mln (3 Analysts)
Q3 Net Income		-$8.1 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for AngioDynamics Inc is $18.00, about 50.8% above its April 1 closing price of $11.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.